Clinical Trial: A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

U.S., May 6 -- ClinicalTrials.gov registry received information related to the study (NCT07568236) titled 'A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)' on April 21.

Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Vasomotor Symptoms Prostate Cancer

Intervention: DRUG: Fezolinetant

Fezolinetant 45 mg orally once daily for 12 weeks.

DRUG: Placebo

Placebo orally once daily for 12 weeks.

Recruitment Status: NOT_YET_RECRUITING

Spons...